Orphazyme stock in free fall after in-court restructuring request
Danish biotech Orphazyme is once again being punished by investors.
.jpg)
by ANDREAS LØNSTRUP, translated by daniel pedersen
On Friday around noon local time, Orphazyme’s stock had dropped 29.6 percent at DKK 5.92 (USD 0.87) on the Copenhagen exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme gets requested observation status
For subscribers
Orphazyme seeks court protection during restructuring
For subscribers
Orphazyme stock plummets following bad news from CHMP
For subscribers
.jpg&w=384&q=75)
